Top ▲

polybromo 1

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 2738

Nomenclature: polybromo 1

Family: Non-enzymatic BRD containing proteins

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 1689 3p21.1 PBRM1 polybromo 1
Mouse - 1704 14 B Pbrm1 polybromo 1
Rat - - 16p16 Pbrm1 polybromo 1
Previous and Unofficial Names Click here for help
BAF180 | PB1
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
PFI-3 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Binding 7.3 pKd 6
pKd 7.3 (Kd 4.8x10-8 M) [6]
Immunopharmacology Comments
We have included PBRM1 in GtoImmuPdb as its repression has been reported to re-sensitise tumour cells with acquired resistance to immunotherapy (e.g. checkpoint blockade by anti-PD-1 or anti-CTLA-4 mAbs) to T cell-mediated attack [3].
General Comments
PBRM1 is a component of the SWI/SNF chromatin remodeling PBAF complex. More than one fifth of human cancers carry mutations in PBAF subunit genes. The PBAF complex is reported to confer tumour cell resistance to T cell-mediated killing [2], suggesting molecular targets for the development of novel interventions to treat cancers driven by perturbed mSWI/SNF activity [5]. PBRM1 has specifically been identified as a potential target for renal cell carcinoma [1,4].


Show »

1. Brugarolas J. (2013) PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J, 19 (4): 324-32. [PMID:23867514]

2. Kadoch C, Crabtree GR. (2015) Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv, 1 (5): e1500447. [PMID:26601204]

3. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P et al.. (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science, 359 (6377): 770-775. [PMID:29301958]

4. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M et al.. (2015) BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn, 15 (9): 1201-10. [PMID:26166446]

5. St Pierre R, Kadoch C. (2017) Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr Opin Genet Dev, 42: 56-67. [PMID:28391084]

6. Structural Genomics Consortium. PFI-3: Selective chemical probe for SMARCA bromodomains. Accessed on 10/11/2014. Modified on 10/11/2014.,

How to cite this page

Non-enzymatic BRD containing proteins: polybromo 1. Last modified on 16/01/2018. Accessed on 21/06/2021. IUPHAR/BPS Guide to PHARMACOLOGY,